| Project/Area Number |
24390458
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHITAKE Yoshiyasu 熊本大学, 医学部附属病院, 非常勤診療医師 (00423682)
HIRAKI Akimitsu 熊本大学, 大学院生命科学研究部, 講師 (60404034)
NAKAYAMA Hideki 熊本大学, 大学院生命科学研究部, 教授 (70381001)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2014: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2012: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
|
|---|
| Keywords | 癌免疫療法 / 口腔癌 / ペプチドワクチン / 癌特異抗原 / アジュバント療法 / 免疫療法 / ペプチドワクチン療法 / アジュバンド療法 |
|---|
| Outline of Final Research Achievements |
In this trial, we analyzed the immune response to and safety and efficacy of vaccine therapy. A total of 21 patients with oral cancer were enrolled in this trial of adjuvant peptide vaccine therapy, and PFS and immunological response were evaluated using enzyme-linked ImmunoSpot (ELISPOT) and pentamer assays. The peptides were subcutaneously administered weekly with IFA. Results: Adjuvant vaccine therapy was well tolerated. The incidence of local recurrence and postoperative metastasis of the A24(+) vaccinated group (n=21) was lower than that of the without this therapy group (n=165). In the A24(+) vaccinated group, the ELISPOT assay identified URLC10, CDCA1 and KOC1-specific CTL responses in 81%, 38% and 71% of the patients, respectively. The patients showing URLC10- , and CDCA1-specific CTL responses demonstrated a lower recurrence than those without CTL induction. The immune response induced by this vaccine may improve the prognosis of patients with advanced oral cancer.
|
